Pfizer's Sandwich site to be enterprise zone; Endo sues Mylan over generic Frova;

@FiercePharma: Antipsychotics beat mood stabilizers for manic episodes, with generic Haldol in first place. Zyprexa, Risperdal next. Story | Follow @FiercePharma

> The U.K. government has officially designated Pfizer's research site in Sandwich as an enterprise zone to help boost development there as the drugmaker pulls most of its operations out. Item | Report

> Endo Pharmaceuticals sued Mylan to bar the generic maker's attempts to make and sell a copycat version of its migraine drug Frova. Story

> Blood-derived therapies maker CSL failed to meet analyst expectations with an 11% decline in annual profits, hurt by the Australian dollar's strength. Article

> Spending on AIDS fell in 2010 for the first time since U.S. and other governments began providing significant funding. More

> Belgium's Omega Pharma is in the final stages of its plan to delist, lacking approval from only a couple of lenders. News

> A new research review found no evidence that women who take aspirin daily have better success with in-vitro fertilization. Report

Biotech News

@FierceBiotech: PhRMA demands an overhaul of FDA's regs on drug names. Report | Follow @FierceBiotech

@JohnCFierce: Cytos hits the wall; laying off most of its workers, circling wagons on lead program. News | Follow @JohnCFierce

@RyanMFierce: A source in small-medium U.S. biopharma has told me taking the trip to meet offshore investigators for trials is well worth the time & money. Follow @RyanMFierce

@MaureenFierce: 11 Biotech Stocks Loved or Hated by Hedge Funds. List | Follow @MaureenFierce

> Roche to hire 200 R&D staffers for new global development center. News

> Updated: Cytos shares nosedive as funding crisis triggers layoffs, R&D halt. Report

> Roche wins early approval for blockbuster melanoma drug vemurafenib. Item 

Drug Delivery News

> "Nanolids" keep meds bottled up until ready for release into tumors. Report

> Microscale gelatin mold can cook up drug-delivering particles. More

> Drug-eluting sinus implant gets FDA premarket approval. Article

> Molecular "Fed-Ex truck" knocks down mutant proteins, delivers genes. Details

> Osmotica's Georgia expansion shows there are jobs in drug delivery. News

> June deals a snapshot of drug-delivery trends. Story

Medical Device News

> AngioDynamics taps DeVivo as CEO. More

> QIAGEN, Pfizer team up on companion diagnostic. Report

> EO2 Concepts looks for a better way to treat wounds. Story

> Ex-Competitive Technologies CEO gets his money. News

> Revolutions Medical gets win against Globe. Details

> Abbott's BVS used in first patient in Japan. Article

And Finally... Every hour of TV watched after the age of 25 reduces life expectancy by 21 minutes on average. Article

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.